ArticleClinical and vaccine immunology : CVI2007
Lipopolysaccharide analogs improve efficacy of acellular pertussis vaccine and reduce type I hypersensitivity in mice.
Article in Clinical and vaccine immunology : CVI, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 44 citations in OpenAlex.
- Mechanisms of natural and vaccine-induced immunity to Bordetella pertussis.PLoS pathogens · 2026Review
- Innovative adjuvant strategies for next-generation pertussis vaccines.Human vaccines & immunotherapeutics · 2025Review
- Acellular Pertussis Vaccines Induce CD8European journal of immunology · 2025Article
- Regulated Expression ofInternational journal of molecular sciences · 2022Article
- RemodelingProceedings of the National Academy of Sciences of the United States of America · 2022Article
- Non-primate animal models for pertussis: back to the drawing board?Applied microbiology and biotechnology · 2022Review
- Vaccine-Induced Cellular Immunity againstVaccines · 2021Review
- Next-Generation Pertussis Vaccines Based on the Induction of Protective T Cells in the Respiratory Tract.Vaccines · 2020Review
- Reactivating Immunity Primed by Acellular Pertussis Vaccines in the Absence of Circulating Antibodies: Enhanced Bacterial Control by TLR9 Rather Than TLR4 Agonist-Including Formulation.Frontiers in immunology · 2019Article
- Composition of pertussis vaccine given to infants determines long-term T cell polarization.The Journal of clinical investigation · 2018Article
- Membrane Vesicles Derived from Bordetella bronchiseptica: Active Constituent of a New Vaccine against Infections Caused by This Pathogen.Applied and environmental microbiology · 2018Article
- Bordetella Pertussis virulence factors in the continuing evolution of whooping cough vaccines for improved performance.Medical microbiology and immunology · 2018Review
- No pain no gain? Adjuvant effects of alum and monophosphoryl lipid A in pertussis and HPV vaccines.Current opinion in immunology · 2017Review
- Association of Vitamin D Receptor Polymorphism with Susceptibility to Symptomatic Pertussis.PloS one · 2016Article
- An improved whole cell pertussis vaccine with reduced content of endotoxin.Human vaccines & immunotherapeutics · 2013Article
- Particle platforms for cancer immunotherapy.International journal of nanomedicine · 2013Review
- Evaluation of a whole-blood cytokine release assay for use in measuring endotoxin activity of group B Neisseria meningitidis vaccines made from lipid A acylation mutants.Clinical and vaccine immunology : CVI · 2010Article
- The role of Toll-like receptor-4 in pertussis vaccine-induced immunity.BMC immunology · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pertussis is an infectious disease of the respiratory tract that is caused by the gram-negative bacterium Bordetella pertussis. Although acellular pertussis (aP) vaccines are safe, they are not fully effective and thus require improvement. In contrast to whole-cell pertussis (wP) vaccines, aP vaccines do not contain lipopolysaccharide (LPS). Monophosphoryl lipid A (MPL) and Neisseria meningitidis LpxL2 LPS have been shown to display immune-stimulating activity while exerting little endotoxin activity. Therefore, we evaluated whether these LPS analogs could increase the efficacy of the aP vaccine. Mice were vaccinated with diphtheria-tetanus-aP vaccine with aluminum, MPL, or LpxL2 LPS adjuvant before intranasal challenge with B. pertussis. Compared to vaccination with the aluminum adjuvant, vaccination with either LPS analog resulted in lower colonization and a higher pertussis toxin-specific serum immunoglobulin G level, indicating increased efficacy. Vaccination with either LPS analog resulted in reduced lung eosinophilia, reduced eosinophil numbers in the bronchoalveolar lavage fluid, and the ex vivo production of interleukin-4 (IL-4) by bronchial lymph node cells and IL-5 by spleen cells, suggesting reduced type I hypersensitivity. Vaccination with either LPS analog increased serum IL-6 levels, although these levels remained well below the level induced by wP, suggesting that supplementation with LPS analogs may induce some reactogenicity but reactogenicity considerably less than that induced by the wP vaccine. In conclusion, these results indicate that supplementation with LPS analogs forms a promising strategy that can be used to improve aP vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.